Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B41 Clinical Trial Validation

Key Points

• To identify a subset of HER2+ breast cancer patients who significantly benefit from trastuzumab using computational methods.
• Utilized computational techniques to derive spatial immune signatures.
• Analyzed data from the NSABP B41 clinical trial.
• Identified biomarkers associated with treatment response.
• A specific subset of HER2+ patients showed enhanced response to trastuzumab.
• Findings indicate the feasibility of using immune architectures to guide therapy selection.
• Supports the role of computational approaches in improving treatment outcomes.